Biogen Inc Total Liabilities
Biogen Inc total liabilities. Based on the latest financial reports, Biogen Inc (BIIB) has total liabilities worth $13.24 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Biogen Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biogen Inc (1985–2025)
Total liabilities of Biogen Inc from 1985 to 2025. This chart illustrates how Biogen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Biogen Inc (BIIB) long-term investment share to see how much of total assets are deployed in long-term investments.
Biogen Inc Competitors by Total Liabilities
The table below lists competitors of Biogen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Adani Enterprises Limited
NSE:ADANIENT
|
India | Rs1.60 Trillion |
|
EQT Corporation
NYSE:EQT
|
USA | $12.46 Billion |
|
China Pacific Insurance Group Co Ltd
SHG:601601
|
China | CN¥2.76 Trillion |
|
Flex Ltd
NASDAQ:FLEX
|
USA | $16.92 Billion |
|
Kenvue Inc.
NYSE:KVUE
|
USA | $16.61 Billion |
|
M&T Bank Corporation
NYSE:MTB
|
USA | $191.31 Billion |
|
Gree Electric Appliances Inc of Zhuhai
SHE:000651
|
China | CN¥250.71 Billion |
|
adidas AG
F:ADS
|
Germany | €14.11 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Biogen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Biogen Inc.
Liquidity & Leverage Metrics
Biogen Inc Total Liabilities Ratios Explained
Biogen Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biogen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biogen Inc (1985–2025)
The table below shows the annual total liabilities of Biogen Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.18 Billion | -1.33% |
| 2024-12-31 | $11.33 Billion | -5.91% |
| 2023-12-31 | $12.05 Billion | +7.88% |
| 2022-12-31 | $11.17 Billion | -13.56% |
| 2021-12-31 | $12.92 Billion | -7.29% |
| 2020-12-31 | $13.93 Billion | +0.27% |
| 2019-12-31 | $13.90 Billion | +13.36% |
| 2018-12-31 | $12.26 Billion | +10.88% |
| 2017-12-31 | $11.05 Billion | +2.85% |
| 2016-12-31 | $10.75 Billion | +6.10% |
| 2015-12-31 | $10.13 Billion | +189.22% |
| 2014-12-31 | $3.50 Billion | +8.02% |
| 2013-12-31 | $3.24 Billion | +2.41% |
| 2012-12-31 | $3.17 Billion | +20.73% |
| 2011-12-31 | $2.62 Billion | -0.77% |
| 2010-12-31 | $2.64 Billion | +15.42% |
| 2009-12-31 | $2.29 Billion | -14.33% |
| 2008-12-31 | $2.67 Billion | -13.62% |
| 2007-12-31 | $3.09 Billion | +120.56% |
| 2006-12-31 | $1.40 Billion | -3.97% |
| 2005-12-31 | $1.46 Billion | -37.54% |
| 2004-12-31 | $2.34 Billion | -4.54% |
| 2003-12-31 | $2.45 Billion | +495.44% |
| 2002-12-31 | $411.57 Million | +10.57% |
| 2001-12-31 | $372.21 Million | +14.37% |
| 2000-12-31 | $325.45 Million | +9.05% |
| 1999-12-31 | $298.44 Million | +44.80% |
| 1998-12-31 | $206.10 Million | -25.74% |
| 1997-12-31 | $277.53 Million | +84.77% |
| 1996-12-31 | $150.20 Million | +74.21% |
| 1995-12-31 | $86.22 Million | +79.90% |
| 1994-12-31 | $47.93 Million | +50.72% |
| 1993-12-31 | $31.80 Million | +21.37% |
| 1992-12-31 | $26.20 Million | +85.82% |
| 1991-12-31 | $14.10 Million | +10.16% |
| 1990-12-31 | $12.80 Million | +113.33% |
| 1989-12-31 | $6.00 Million | -53.49% |
| 1988-12-31 | $12.90 Million | +0.78% |
| 1987-12-31 | $12.80 Million | +10.34% |
| 1986-12-31 | $11.60 Million | +6.42% |
| 1985-12-31 | $10.90 Million | -- |
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more